Crucell N.V. Reports First Orders For Contract Manufacturing Agreement With Wyeth Biotech

Published: Dec 15, 2006

Leiden, The Netherlands, December 15, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has received its first orders for the CMO agreement with New Jersey-headquartered Wyeth Biotech. The CMO agreement for formulation and filing of a vaccine was finalized end 2005 and will have the first business impact for Crucell in 2007. The vaccine will be supplied from Crucell's Swiss subsidiary.

Back to news